Journal of Thrombosis and Thrombolysis

, Volume 19, Issue 2, pp 105–113 | Cite as

Enoxaparin in Clinical Practice and Clinical Trials of Non-ST-Elevation Acute Coronary Syndrome (NSTE-ACS)

Article

Abstract

Non-ST elevation Acute Coronary Syndrome (NSTE-ACS) is a myocardial ischemic disorder frequently caused by coronary artery plaque rupture and partial or transient vessel occlusion. Platelets and thrombin play pivotal roles in formation and propagation of thrombus at the site of plaque disruption and embolization into the vascular bed. With the outgoing development of antithrombotic, antiplatelet, and mechanical therapies, the management of NSTE-ACS is constantly evolving. Heparins are the cornerstone of antithrombotic therapy in the current management of NSTE-ACS. Unfractionated heparin and fractionated heparins like enoxaparin have been studied in several large clinical trials and found to be effective in reducing death and myocardial infarction rates. For medical management alone or primarily (conservative strategy), enoxaparin has been shown to be superior to unfractionated heparin. With an early invasive strategy providing better clinical outcome compared to a conservative strategy, the paradigm of ACS management has shifted in favor of early (within 48 hours of admission) cardiac catheterization. The effectiveness of enoxaparin compared to unfractionated heparin is now being re-considered in the era of poly-pharmacotherapy and an early invasive strategy for ACS management. We review the role of enoxaparin in the contemporary treatment of NSTE-ACS utilizing recent clinical trial data.

Key Words

heparin enoxaparin acute coronary syndrome clinical trials 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Braunwald E, Antmann EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000;36:970–972.CrossRefPubMedGoogle Scholar
  2. 2.
    Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: A meta-analysis. JAMA 1996;276:811–815.CrossRefPubMedGoogle Scholar
  3. 3.
    Weitz JL. Low molecular weight heparins. N Engl J Med 1997;337:688–698.CrossRefPubMedGoogle Scholar
  4. 4.
    Cohen M, Demers C, Gurfinkel EP, et al. For the efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447–452.CrossRefPubMedGoogle Scholar
  5. 5.
    Antman E, McCabe CH, Gurfinkel EP, et al. For the TIMI-11 B investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI-11 B) trial. Circulation 1999;100:1593–1601.PubMedGoogle Scholar
  6. 6.
    Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI-11B-ESSENCE meta-analysis. Circulation 1999;100:1602–1608.PubMedGoogle Scholar
  7. 7.
    Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Summary article. Circulation 2002;106:1893–1900.CrossRefPubMedGoogle Scholar
  8. 8.
    Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107:238–244.CrossRefPubMedGoogle Scholar
  9. 9.
    Cohen M, Theroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study. Am Heart J 2002;144:470–477.CrossRefPubMedGoogle Scholar
  10. 10.
    Blazing MA, de Lemos JA, White HD, et al. For the A to Z investigators. Safety and efficacy of enoxaparin versus unfractionated heparin in patients with non-ST segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial. JAMA 2004;292:55–64.CrossRefPubMedGoogle Scholar
  11. 11.
    De Lemos JA, Blazing MA, Wiviott SD, et al. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: Results from the A phase of the A-to-Z trial. Eur Heart J 2004;251:688–1694.Google Scholar
  12. 12.
    Neumann FJ, Kastrati A, Murray P, et al. Evaluation of prolonged anti-thrombotic pretreatment (“cooling-off” strategy) before intervention in patients with unstable coronary syndromes: A randomized controlled (ISAR-COOL) trial. JAMA 2003;290:1593–1599.CrossRefPubMedGoogle Scholar
  13. 13.
    The Fragmin and Fast Revascularization During In Stability in Coronary Artery Disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomized multi-center study. Lancet 1999;354:708–715.Google Scholar
  14. 14.
    TACTICS-TIMI-18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879– 1887.Google Scholar
  15. 15.
    Fox KAA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST elevation myocardial infarction: The British Heart Foundation RITA-3 randomized trial. Lancet 2002;360:743–751.CrossRefPubMedGoogle Scholar
  16. 16.
    Kereiakes DJ, Fry E, Matthai W, et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: “NICE guys finish first. J Invasive Cardiol 2000;SupplA:1A–5A.Google Scholar
  17. 17.
    Lee DS, Bhatt DL, Moliterno DJ, et al. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. J Invasive Cardiol 2004;16:46–51.PubMedGoogle Scholar
  18. 18.
    The SYNERGY Trial Investigators. Enoxaparin versus unfractionated heparin in high risk patients with non–ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 2004;292:45–54.Google Scholar
  19. 19.
    Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for anti-thrombin therapy in non–ST-segment elevation acute coronary syndromes: A systematic review. JAMA 2004;292:89–96.CrossRefPubMedGoogle Scholar
  20. 20.
    Anand SS, Yusuf S, Pogue J, et al. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin: Organization to assess the strategies for ischemic syndrome (OASIS-2) pilot study. Circulation 2003;107:2884–2888.CrossRefPubMedGoogle Scholar
  21. 21.
    Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary interventions following subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658–663.PubMedGoogle Scholar
  22. 22.
    Martin JL, Fry ETA, Sanderink GCM, et al. Reliable anticoagulation with enoxaparin inpatients undergoing percutaneous coronary intervention (PCI): The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 2004;61:163–170.CrossRefPubMedGoogle Scholar
  23. 23.
    Montalescot G, Collet JP, Tanguy ML, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004;110:392–398.CrossRefPubMedGoogle Scholar
  24. 24.
    Kereiakes DJ, Grines C, Fry E, et al. NICE 1 and NICE 4 Investigators. National Investigators Collaborating on Enoxaparin. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001;13:272–278.PubMedGoogle Scholar
  25. 25.
    Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 2001;119:64S–94S.CrossRefPubMedGoogle Scholar
  26. 26.
    Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaprin in eleective percutaneous coronary intervention. J Am Coll Cardiol 2002;40:1943–1950.CrossRefPubMedGoogle Scholar
  27. 27.
    Moliterno DJ, Hermiller JB, Kereiakes DJ, et al. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1132–1139.CrossRefPubMedGoogle Scholar
  28. 28.
    Collet JP, Montalescot G, Fine E, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 2003;41:8–14.CrossRefPubMedGoogle Scholar
  29. 29.
    Exaire JE, Tcheng JE, Kereiakes DJ, et al. Closure devices and vascular complications among PCI patients receiving Enoxaparin, GPIIb/IIIa inhibitors and clopidogrel. Catheter Cardiovasc Interv 2005;64:369–372.CrossRefPubMedGoogle Scholar
  30. 30.
    Cantor WJ, Goodman SG, Gallup D, et al. Major access site bleeding in acute coronary syndrome patients undergoing early invasive management can be reduced with radial access and smaller sheath sizes; observations from the SYNERGY trial. J Am Coll Cardiol 2005; abstract 191A 45(3): (Suppl A):1003–1200.Google Scholar
  31. 31.
    Bittl JA, Stony J, Brinker JA, et al. Treatment with Bivalirudin (Hirulog) as compared to heparin during coronary angioplasty for unstable or post-infarction angina. N Engl J Med 1995;333:764–769.CrossRefPubMedGoogle Scholar
  32. 32.
    Lincoff MA, Kleiman NS, Kereiakes DJ, et al. Long term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blocade versus heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization. REPLACE-2 randomized trial. JAMA 2004;292:696– 703.CrossRefPubMedGoogle Scholar
  33. 33.
    Stone GW, Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale. Am Heart J 2004;148:764–775.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  1. 1.Gill Heart Institute and the Division of Cardiovascular MedicineUniversity of KentuckyLexington
  2. 2.Division of Cardiovascular MedicineUniversity of KentuckyLexington

Personalised recommendations